Persistent allergic rhinitis (AR) and asthma constitute a common comorbidity. Combined treatment is recommended by prescribing intranasal plus oral inhaled corticosteroids.
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This study was carried out to assess the efficacy of an alternative regimen to treat this condition.
All recruited patients suffered from persistent AR and asthma. Diagnosis and classification of AR and asthma were based on international guidelines. The experimental group received fluticasone propionate (FP), 500 mg/day during six weeks, inhaled exclusively through the nose using a valved large volume spacer attached to a facemask. The comparison group also received the same dose of orally inhaled FP, during the same time period, plus intranasal aqueous fluticasone, 200 mg/day. There were no statistical differences between both groups regarding AR and asthma severity, clinical scores, acoustic rhinometry, lung function, and FeNO upon admission and during the follow up period. Intragroup analysis demonstrated a significant improvement for allergic rhinitis and asthma scores as well as for FeNO from admission to the sixth week (p < 0.01) in both groups.
Results suggest that exclusive nasally inhaled fluticasone propionate should be considered as an alternative step in the management of patients suffering from AR and asthma comorbidity. ª 2010 Elsevier Ltd. All rights reserved.
Introduction
Three published studies demonstrated the efficacy of the simultaneous treatment of persistent allergic rhinitis (AR) and asthma using the nasal route for inhaled corticosteroids.
1e3 However this therapeutic strategy was evaluated through conventional clinical and spirometric features but not with more sophisticated measurements as acoustic rhinometry and the fraction of exhaled nitric oxide (FeNO).
The objective of this study was to assess the efficacy of nasally inhaled fluticasone propionate (FP), as a unified treatment of AR and asthma.
Materials and methods
Patients aged 10e23 years with persistent asthma with postbronchodilator forced expiratory volume in 1 s (FEV 1 ) 4 response to b-agonists !12% in forced expiratory volume (FEV 1 ) 4 and persistent allergic rhinitis 5 were enrolled. We excluded non-steroid naïve asthmatic patients, who had any exacerbations in the four weeks preceding the admission, patients suffering from severe persistent asthma (e.g., prebronchodilator FEV 1 60% predicted), who used systemic steroids, intranasal corticosteroids, topic vasoconstrictors, anti-histamine agents or leukotriene modifier in the last 30 days, specific desensitization in the previous three months upon admission, tobacco smokers, upper respiratory tract infection, and chronic concurrent diseases.
AR was assessed by Wilson's clinical score. 6 By adding up we reached the final score, characterizing as mild, moderate and severe based on the scores of lower than 6, 7e12 and 13e18, respectively. Likewise, the score described by Rosier et al was used to classify asthma severity, 7 as follows: mild, moderate and severe when the score add up to 2e8, 9e14 and 15e19 points, respectively.
The study lasted six weeks. Pulmonary function testing was performed and interpreted according to the American Thoracic Society (ATS) criteria using the Stead-Wells DS II PLUS 10 L spirometer (Warren-Collins, USA). FeNO was measured by using online single breath method with Nitric 9 to measure nasal cavity volume, calculated from the area-distance expressed in cm 3 . In the final analysis we considered the summation of the values of both nostrils. 10 Patients were randomly assigned in two groups: the experimental one was treated with exclusive nasal inhalation of fluticasone propionate (FP) (Flixotide Ò , GlaxoSmithKline, Brazil, 250 mg/puff), 500 mg/day, through a large volume pear shaped valved spacer (Flumax Ò , Flumax Medical Equipments, Brazil) attached to a facemask. After each puff subjects repeatedly inhaled FP deeply through their noses for 30 s keeping their mouth closed. The comparison group received the dual conventional treatment, i.e., the same dose of orally inhaled FP through the mouthpiece of the same spacer to treat asthma and, aqueous intranasal fluticasone (Flixonase Ò , GlaxoSmithKline, Brazil, 200 mg/day) for AR. The study protocol and the written consent were approved by the local ethics committee.
Descriptive and analytical statistics, as well as the difference between clinical scores, functional parameters were calculated for each group by paired t-Student test upon admission and on the last visit. For these intra-group comparisons, statistically significant differences were evaluated after a Bonferroni correction, which yielded a pvalue of 0.012 for the differences observed, considering four comparison pairs.
Results
Among the 37 recruited patients 30 of them completed the study protocol. Upon admission and during the follow up there were no statistically significant differences between the two groups regarding the studied variables (see Table 1 ). From admission to the sixth week, FeNO levels dropped 46.8% and 56.7% and acoustic rhinometry values increased 15.2% and 12% in the experimental and comparison group, respectively. There were no significant differences when data were re-analysed after exclusion of drop outs. Table 2 shows intragroup analysis comparisons between the initial and final mean values of clinical scores, acoustic rhinometry, pulmonary function tests and FeNO. There were an evident improvement for all of these outcomes, but a statistically significant difference was observed only for AR and asthma scores, and FeNO.
Discussion
Studies that assessed the efficacy of nasally inhaled corticosteroids for the concomitant treatment of AR and asthma are scarce 1e3 and none of them included acoustic rhinometry and FeNO measurements.
In two studies, patients were treated previously for asthma, differently to the present one. Pedersen et al assessed 24 children receiving budesonide inhaled nasally through a non-commercialized nozzle during three weeks. 1 Compared with placebo, budesonide treatment resulted in a significant reduction in nasal and asthma symptoms, and in an increase of peak expiratory flow and nasal peak inspiratory flow (p-values < 0.05). Among 75 patients evaluated by Camargos et al, 38 received nasally inhaled beclometasone 2 ; the control group used aqueous beclometasone for AR.
2 There were also no statistically significant differences between both groups (p-values ! 0.11).
In the third one 60 steroid-naive patients were treated with nasally or orally inhaled FP, while the comparison group received 0.9% saline solution for AR. 3 Again, there were no statistically significant differences in asthma outcomes (p-values ! 0.15), but the intervention group had significant improvements in AR symptoms when compared to comparison group (almost all p-values 0.01).
Due to small sample size, our study is clearly underpowered (power average was approximately 10% for the studied outcomes). However, clinical and spirometric findings are in agreement with the results observed in the three above mentioned studies. Moreover, our results were reinforced by the findings of the two new measurements, i.e., acoustic rhinometry and FeNO which favored this alternative way to treat AR-asthma comorbidity. Finally, nasally inhaled corticosteroid has the advantage of treating it with one single medicine in a rational and low cost manner.
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